CAR-T therapy takes on scleroderma: a new hope for patients
NCT ID NCT06400303
First seen Nov 01, 2025 · Last updated May 25, 2026 · Updated 24 times
Summary
This early-stage study tests a new treatment called KYV-101 for people with systemic sclerosis, a rare autoimmune disease that causes skin and organ hardening. The therapy uses a patient's own modified immune cells to target and destroy faulty B-cells. The main goals are to check safety and see if it can improve disease symptoms.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Northwell Health
Great Neck, New York, 11021, United States
-
Stanford University Medical Center
Palo Alto, California, 94305, United States
Conditions
Explore the condition pages connected to this study.